Compare Inovio Pharmaceuticals Inc (INO) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Petróleo Brasileiro SA — how do they compare? Inovio Pharmaceuticals Inc trades at $0.88 (market cap $78.67M), while Petróleo Brasileiro SA trades at $17.75 (market cap $110.21B). The key difference: Petróleo Brasileiro SA is far larger — about 1400.9× Inovio Pharmaceuticals Inc's market cap, and Petróleo Brasileiro SA pays a 9.51% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PBR | |
|---|---|---|
Market Cap | $78.67M | $110.21B |
Sector | Health | Technology |
52-Week High | $2.87 | $22.03 |
52-Week Low | $0.66 | $11.54 |
Enterprise Value | $50.00M | $170.63B |
Dividend Yield | — | 9.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Petrobras (PBR) trades at $17.76, down 3.11% today, amid bearish technical signals despite strong Q2 2026 results showing record production and earnings growth. The company maintains robust fundamentals with a P/E of 4.53, ROE of 30.77%, and consistent dividend payments, though cash flow turned negative in 2026. Recent news highlights production exceeding forecasts and strategic expansions in deepwater operations.
PBR presents a value opportunity with attractive valuations and high profitability, but faces headwinds from regulatory uncertainty and volatile oil prices. Analyst consensus is bullish (50% Buy ratings), yet technical indicators suggest near-term pressure. Investors should weigh strong fundamentals against geopolitical and operational risks in the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
